S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
66,000% upside on tiny biotech? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Forecast, Price & News

$15.93
-0.78 (-4.67%)
(As of 06/5/2023 ET)
Compare
Today's Range
$15.65
$16.72
50-Day Range
$15.84
$22.01
52-Week Range
$11.13
$30.79
Volume
51,267 shs
Average Volume
88,206 shs
Market Capitalization
$395.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.00

Aerovate Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Bearish
5.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.42 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.75) to ($2.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.55 out of 5 stars

Medical Sector

794th out of 985 stocks

Pharmaceutical Preparations Industry

394th out of 481 stocks


AVTE stock logo

About Aerovate Therapeutics (NASDAQ:AVTE) Stock

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTE Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Aerovate Therapeutics (AVTE) Receives a Buy from Wedbush
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 5.3%
See More Headlines

AVTE Price History

AVTE Company Calendar

Last Earnings
3/29/2023
Today
6/05/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTE
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.00
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+144.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.19 per share

Miscellaneous

Free Float
20,394,000
Market Cap
$395.22 million
Optionable
Not Optionable
Beta
0.33

Key Executives

  • Mr. Timothy P. Noyes M.B.A. (Age 61)
    CEO & Director
    Comp: $655.65k
  • Dr. Benjamin T. Dake Ph.D. (Age 47)
    Founder, Pres, COO & Sec.
    Comp: $435.5k
  • Mr. George A. Eldridge (Age 60)
    CFO & Treasurer
    Comp: $454.64k
  • Mr. Hunter Gillies M.D. (Age 57)
    Chief Medical Officer
    Comp: $512.74k
  • Dr. Ralph W. Niven M.B.A. (Age 63)
    M.R, Ph.D., Pharm.S, Chief Scientific Officer
  • Mr. Timothy J. Pigot
    Sr. VP of Commercial
  • Ms. Donna Dea
    Head of Regulatory Affairs
  • Dr. Marinus Verwijs Ph.D. (Age 47)
    Sr. VP of CMC
  • Ms. Susan Fischer
    Sr. VP of Devel. Operations
  • Mr. Stephen Yu
    Sr. VP of Quality













AVTE Stock - Frequently Asked Questions

Should I buy or sell Aerovate Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVTE shares.
View AVTE analyst ratings
or view top-rated stocks.

What is Aerovate Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued 12 month price targets for Aerovate Therapeutics' shares. Their AVTE share price forecasts range from $27.00 to $54.00. On average, they expect the company's share price to reach $39.00 in the next twelve months. This suggests a possible upside of 144.8% from the stock's current price.
View analysts price targets for AVTE
or view top-rated stocks among Wall Street analysts.

How have AVTE shares performed in 2023?

Aerovate Therapeutics' stock was trading at $29.30 at the start of the year. Since then, AVTE stock has decreased by 45.6% and is now trading at $15.93.
View the best growth stocks for 2023 here
.

Are investors shorting Aerovate Therapeutics?

Aerovate Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 913,900 shares, a decrease of 5.3% from the April 30th total of 965,000 shares. Based on an average daily trading volume, of 72,700 shares, the days-to-cover ratio is presently 12.6 days. Approximately 5.9% of the shares of the stock are short sold.
View Aerovate Therapeutics' Short Interest
.

When is Aerovate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our AVTE earnings forecast
.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.03.

What ETFs hold Aerovate Therapeutics' stock?

ETFs with the largest weight of Aerovate Therapeutics (NASDAQ:AVTE) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), ALPS Medical Breakthroughs ETF (SBIO),

When did Aerovate Therapeutics IPO?

(AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

What is Aerovate Therapeutics' stock symbol?

Aerovate Therapeutics trades on the NASDAQ under the ticker symbol "AVTE."

Who are Aerovate Therapeutics' major shareholders?

Aerovate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (8.22%), Baker BROS. Advisors LP (7.91%), Great Point Partners LLC (3.05%), BlackRock Inc. (2.42%), FMR LLC (2.30%) and Ghost Tree Capital LLC (0.81%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes.
View institutional ownership trends
.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerovate Therapeutics' stock price today?

One share of AVTE stock can currently be purchased for approximately $15.93.

How much money does Aerovate Therapeutics make?

Aerovate Therapeutics (NASDAQ:AVTE) has a market capitalization of $395.22 million. The company earns $-51,510,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

How can I contact Aerovate Therapeutics?

The official website for the company is aerovatetx.com. The company can be reached via phone at 617-443-2400 or via email at ir@aerovatetx.com.

This page (NASDAQ:AVTE) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -